2024
rBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors
Wang X, Wei W. rBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors. Contemporary Clinical Trials 2024, 140: 107505. PMID: 38521384, DOI: 10.1016/j.cct.2024.107505.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBayes TheoremClinical Trials, Phase II as TopicComputer SimulationHumansModels, StatisticalNeoplasmsResearch DesignConceptsPhase II basket trialRobust Bayesian modelBasket trial designBiomarker-defined subgroupsMixture priorsBinary endpointsModel averaging methodPosterior distributionBayesian modelBasket trialsSimulation studyEra of targeted therapyDevelopment of targeted agentsPriorsAverage methodGenomic alterationsPatient populationNovel treatmentAntitumor activityPosterior weightsEarly phase oncology trialsStatistical powerOncology trialsTrial designTrials
2019
A two‐stage phase II clinical trial design with nested criteria for early stopping and efficacy
DeVeaux M, Kane M, Wei W, Zelterman D. A two‐stage phase II clinical trial design with nested criteria for early stopping and efficacy. Pharmaceutical Statistics 2019, 18: 700-713. PMID: 31507079, PMCID: PMC6996237, DOI: 10.1002/pst.1965.Peer-Reviewed Original Research